DOCSLIB.ORG

2831 Neonatal Hypoglycemia Associated with Anterior

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2831 Neonatal Hypoglycemia Associated with Anterior NEONATAL HYPOGLYCEMIA ASSOCIATED WITH ANTERIOR STUDIES OF PLASMA CALCITONIN IN HYPOPITUITARISM AND 2831 HYPOPITUITARISM. David R. Brown and David B. Klain HYPOTHYROIDISM. Dennis E. Carey, Kenneth Lee Jones, Children's Health Center and Deot. of Peds. Univer- Jacqueline G. Parthemore, and Leonard J. Deftos. sity of Minnesota, Minneapolis. (spon. by Robert A. Ulstrom.) of California San Dieno- School of Medicine and San We have observed the association of profound hypoglycemia and Diego VA Hospital. Departments of Pediatrics and Medicine. La anterior hypopituitarism in four newborns. All presented with Jolla, California 92093 hypoglycemia during the first 30 hours of life, which reached The secretion of calcitonin (CT) was studied in 17 children, levels less than 10 mg.%. Rates of 20-30 mg./kg./min. of 20% 10 with hypopituitarism and 7 with agoitrous hypothyroidism. dextrose were required to maintain glucose levels above 30 mg.%. Plasma CT levels were measured by radioimmunoassay in the basal All infants were products of complicated pregnancies and deliver state and following infusion of pentagast#n (0.5 pg/kg) and 10 ies and had APGAR scores of five or less at one and five minutes minute infusions of calcium (2.3 mg/kg Ca as CaCl ). Of the Measurements of anterior pituitary function including serum 10 children who have hypopituitarism, 5 were studie3 before and TSH, T4, ACTH, cortisol and growth hormone, in addition to meta- after one year of human growth hormone (HGH) therapy and 5 were pyrone and cosyntropin stimulation, revealed anterior panhypo- studied before treatment only. Basal and peak response CT level: pituitarism in three infants and isolated ACTH deficiency in the were essentially unchanged by HGH. In the patients with hypo- other. Posterior pituitary function was normal in all cases. pituitarism, CT levels increased from 41.9 ? 5.1 pg/ml to a Unresponsiveness of TSH to intravenous thyrotropin releasing peak of 67.4 + 10 pg/ml after pentagastrin and from 38.8 t 5.2 hormone (TRH) and normal serum prolactin levels further support pg/ml to a peak of 107 + 14.9 pg/ml after calcium infusion. In anterior pituitary dysfunction in contrast to a hypothalamic the cretins, CT levels increased from 33.8 ? 6.5 pg/ml to 35.8 etiology. Autopsy on one infant revealed no anterior pituitary + 7 pg/ml following pentagastrin and from 31.4 + 5.9 pg/ml to tissue. The three surviving patients are all doing well on 40 + 4.9 pg/ml following calcium. Although basal levels of CT appropriate hormone replacement. Micropenis was present in the seemed to be lower in cretins, these values could not be rigor- one male and all infants showed a widening of the midfacies. ously validated. The patients with hypopituitarism had greater This unappreciated cause of early neonatal hypoglycemia may 1 CT responses than the cretins, especially to calcium infusion. be related to birth hypoxia or anatomic malformation of the ant- 8 These studies suggest that children with hypopituitarism have erior pituitary and its rudiments. These may be more susceptibl a greater CT response to calcium infusion than do normal adults to events at birth than previously appreciated and consequently and that CT secretion is abnormal in patients with athyreotic Ithis system should be more agressively evaluated in newborns. cretinism. ANTIBODIES TO LUTEINIZING HORMONE IN A PATIENT TREAT- ED WITH GROWTH HORMONE. S. Burstein, F.A. Conte. S .L. ROWTH RETARDATION S. Castel Is, A. Brown, N. Kaplan, and M.M. Grumbach. Dept. Pediatrics, Univ. of E. Dunn, and N. Muthukrishnan. Depts. of- an Francisco, San Francisco, Ca. ology, SUNY, Downstate Med. Ctr., G'klyn, N.Y Many clinical grade preparations of hGH (human growth hormone) Eight sickle cell patients, 9-15 yr., with severe growth re- are contaminated with hLH and hFSH. However, no evidence of a tardation, retarded bone age and delayed puberty had normal ser- clinical effect of such contamination has been described. We re- um concentrations of T4,T3,PRL after chlorpromazine stimulation, port the development of antibodies to hLH in a patient treated and normal adrenal functions measured by circadian variation of with hGH for isolated GH deficiency. plasma cortisol, plasma cortisol during hypoglycemia, ACTH and J.C. was first investigated for short stature at 7-11/12 years metyrapone tests. hGH response to insulin-induced hypoglycemia and GH therapy was begun at 8-9/12 years for a diagnosis of iso- was abnormally low in 4/8. Four males and 3 females had ele- lated GH deficiency. On LRF (luteinizing hormone releasing factor vated plasma concentrations of LH and FSH; 4 males had low testing, the LH rose from 0.8 to 1.2 ng/ml (LER 960); FSH respons plasma testosterone and 3 females had low plasma estradiol. The slso was normal. At 11-11/12 years the patient was still prepu- severe growth retardation seems to result from a primary gonadal ~ertalwith undetectable testosterone levels. A repeat LRF test hypofunction associated in some cases with hGH deficiency. revealed an "apparent" basal plasma LH of 25.4 ng/ml. Further Ethylestrenol, a synthetic androgen, was administered for one ;tudies indicated that his serum had antibodies to hLH which hav year at 2 to 4 rng daily. Range of growth rate before therapy >ersisted for over 2-112 years on growth hormone therapy without was 1.2-4.9 cm/yr; during therapy was 3.6-15.6 cm/yr. There waz :he development of significant GH antibodies. l251-h~was bound no acceleration in bone age. No significant changes in Hgb., :o his serum in a displacable fashion; hFSH and hTSH displaced Hct., reticulocyte count and fetal Hgb occurred. A striking :his tracer only at doses compatible with contamination of these finding was a consistent increase in red cell mass measured by itandards by hLH. Radioiodinated hFSH, hTSH and hLH-a were not 51Cr tagging of the RBC. There was a tendency towards a further ound; the antibody is directed against the LH-6 subunit. The shortening of an already short 51~rRBC survival in 4/6. There inding capacity of the serum and the equilibrium constant for were no consistent changes in an already very low plasma 59~e he binding reaction are sufficiently great to be physiologically disappearance rate. Ethylestrenol, was found to stimulate ignificant. growth without accelerating bone maturation, and to increase rec cell mass without prolonging red cell survival. I Supported by NIH Grant RR-318 A Virilizing A renocortical Tumor in a Female Infant: SteroidogenesidS In Vivo and In Vitro. Lucienne A. Cahen, Dorothy B. Villee, M. Linda Powers, and John F. Crigler, Jr., Harvard Med. Sch., Children's Hosp. Med. Cen., Endocrine Division, Boston, Mass. The peripheral Aetaholisn of TI, has heen notcd to h~ altered Normal adrenal and adrenal tumor cells from a female infant in a number of non-thvroiclal illnesses. The known relationsl~ip with a virilizing adrenal tumor were grown in tissue culture £01 of thyroid hormones and oxvRen consumption led to these studies a period of 7 weeks with and without ACTH (0.1 unit/ml). The investigatinp the effects of hvnoxia on nerinllcrnl 7-t.taholi5n or cells grew well and continued to produce steroid hormones, as TI,. TI,,T2, rT? and TT.11 levels were c!rtcrmine<! in natients !lit!> status astl~maticosand cvanotic Ilenrt ,lisr,n4~,nnne nf r.!'lnr WPrr measured by radioimmunoassay of individual steroids in the cul- ture medium. Compared to normal cells, tumor cells with no ACTH cachectic or malnor~risl,rd. 'lean renul ts(+Sr'')?rr tabulated '~eln!il added produced equivalent amounts of cortisol, 180H corticoster- "('7 T/, 7 rT TC!' one, and 180H deoxycorticosterone, but lesser amounts of dehydrc mnli~ up/rll nr/dl ny?~1 uU/i.l lnh .qth.7 ?l.6+1.To /#.Qtn. 1 epiandosterone (DHA), androstenedione (A), testosterone (T) and Controls Q.15t0.5 (17 h.752n.9 77.6+7.5 ?/I .7+fi .07 5./~5+!.^ progesterone. Normal cells exposed to ACTH showed an increase ir Chronic 'lvpoxia O7.7th.I 17.7tC.1 1.77t.l.h all steroids measured whereas ACTH-exposed tumor cells showed ar Acute Ilynoxia 66 7.hQf1.1 - 3 sianificant decrease in T7 levels wit!^ a sipnifi- increase principally in DHA, consistent with a deficiency in 3b There &-as hydroxysteroid dehydrogenase. Concentrations of DHA, A and T in cant incrca7e in rT7 in the patient? ~.ithr'ironic hv~oxin.i'ven the patient's serum were elevated before the adrenal tumor was hvnoxia of short duration raused a significant increase in rT7. removed. The relative concentration of the three androgens in T4 levels were also lower in the c'lrnnic hvpoxic proun. These media of tumor cells in vitro resembled that in patient's serum data are similar to the finrlin~sohtatner? drlrinp catnhnlic non- in vivo. These studies demonstrate that both normal and tumor thyroidal illnesses. Tbese alterations in t!i-rroirl Fllnction tcnts cells of adrenal can be maintained for a long time in vitro, nav reflect an afiantive nllenonenon at tile cellular level, i.e.,a that they retain their ability to respond to ACTH and that they ~rotectivemechanism vhich ran divert Tq to rT7, or convernelv, produce their characteristic steroids. The tumor cells appear t( as during cold exposure, can increase nrnductinn of T?. Tn lipht of these data correlatinp hvnnxia and Chvrnid hormones. the suo- have a 36-hydroxysteroid dehydrogenase deficiency. Supported by the National Foundation, the Grant Foundation, qestions that the low thvroid function levels in 'lnS infants mav be etiolosicallv related to R?S mav need to he reevaluated.
Load more

Recommended publications
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • Progestin-Only Systemic Hormone Therapy for Menopausal Hot Flashes
    EDITORIAL Progestin-only systemic hormone therapy for menopausal hot flashes Clinicians treating postmenopausal hot flashes often recommend “systemic estrogen treatment.” However, progestin-only therapy also can effectively treat hot flashes and is an option for women with a contraindication to estrogen therapy. Robert L. Barbieri, MD Editor in Chief, OBG MANAGEMENT Chair, Obstetrics and Gynecology Brigham and Women’s Hospital Boston, Massachusetts Kate Macy Ladd Professor of Obstetrics, Gynecology and Reproductive Biology Harvard Medical School he field of menopause medi- women. In one study, 133 postmeno- in postmenopausal women with cine is dominated by studies pausal women with an average age an American Heart Association risk T documenting the effective- of 55 years and approximately 3 years score greater than 10% over 10 years.3 ness of systemic estrogen or estro- from their last menstrual period were Additional contraindications to sys- gen-progestin hormone therapy for randomly assigned to 12 weeks of temic estrogen include women with the treatment of hot flashes caused treatment with placebo or micronized cardiac disease who have a throm- by hypoestrogenism. The effective- progesterone 300 mg daily taken at bophilia, such as the Factor V Leiden ness of progestin-only systemic bedtime.1 Mean serum progesterone mutation.4 hormone therapy for the treatment levels were 0.28 ng/mL (0.89 nM) and For women who are at high risk of hot flashes is much less studied 27 ng/mL (86 nM) in the women taking for estrogen-induced cardiovascu- and seldom is utilized in clinical placebo and micronized progesterone, lar events, micronized progesterone practice.
    [Show full text]
  • Informed Consent for Feminizing Hormone Therapy
    Informed Consent for Feminizing Hormone Therapy For _________________________ Date of Birth: _____________ Name Used: ____________________ Patient Name as listed in chart Name if different from chart This form will assist you (and your guardian) to think through the expected effects of hormone therapy including possible unwanted side effects. You are encouraged to talk about this treatment with your medical provider and decide if hormone therapy is right for you (your child). By signing this form, you are stating that you have discussed the effects and risks of this medication with your medical provider or a member of the medical team and that you understand and accept these effects and possible risks. You (and your guardian) may ask questions and talk about any concerns you have related to this treatment at any time in this process. Estrogen (usually estradiol) is used to feminize the body (make it look more traditionally female). This medical treatment will reduce some male features and increase some female features of the body. Androgen (testosterone) blockers further decrease the amount of and/or block the effect of testosterone and masculinization of the body. Your medical provider will help decide which form and the amount of estrogen (shots, pills, gels, patches) and androgen blockers (pills, gels, shots, implanted) that are best for you based on your personal needs and any medical or mental health conditions you might have. Each person’s body responds to estrogen differently and it is hard to promise or predict with certainty how each person may respond to treatment. Your medical provider will talk with you throughout the treatment and will help you achieve the best results safely.
    [Show full text]
  • A Guide to Feminizing Hormones – Estrogen
    1 | Feminizing Hormones ​ ​ A Guide to Feminizing Hormones Hormone therapy is an option that can help transgender and gender-diverse people feel more comfortable in their bodies. Like other medical treatments, there are benefits and risks. Knowing what to expect will help us work together to maximize the benefits and minimize the risks. What are hormones? Hormones are chemical messengers that tell the body’s cells how to function, ​ when to grow, when to divide, and when to die. They regulate many functions, including growth, sex drive, hunger, thirst, digestion, metabolism, fat burning & storage, blood sugar, cholesterol levels, and reproduction. What are sex hormones? Sex hormones regulate the development of sex characteristics, including the sex ​ organs such as genitals and ovaries/testicles. Sex hormones also affect the secondary sex characteristics that typically develop at puberty, like facial and body hair, bone growth, breast growth, and voice changes. There are three categories of sex hormones in the body: • Androgens: testosterone, dehydroepiandrosterone (DHEA), ​ dihydrotestosterone (DHT) • Estrogens: estradiol, estriol, estrone ​ • Progestin: progesterone ​ Generally, “males” tend to have higher androgen levels, and “females” tend to have higher levels of estrogens and progestogens. What is hormone therapy? Hormone therapy is taking medicine to change the levels of sex hormones in your body. Changing these levels will affect your hair growth, voice pitch, fat distribution, muscle mass, and other features associated with sex and gender. Feminizing hormone therapy can help make the body look and feel less “masculine” and more “feminine" — making your body more closely match your identity. What medicines are involved? There are different kinds of medicines used to change the levels of sex hormones in your body.
    [Show full text]
  • 1. Two Components, Two Sets of Lecturers
    Conditions 1. Two components, two sets of lecturers. 2. Lectures 1-5 Prof. F. Hudecz Lectures 6-9 Dr. Gy. Domány Lectures 10-12 Dr. P. Buzder-Lantos 3. Examination: two parts determined by the lecturers and one mark. - option A: written test - option B: presentation based on literature - option C: oral examination 4. Participation at lectures > 70 % [email protected] Some Approved Peptide Pharmaceuticals and their Methods of Manufacture First generatioin Second generation New generation Oxytocin (L) Carbetocin (S) Abarelix (GnRH) (L) ACTH (1-24) & (1-39) (L,S) Terlipressin (L,S) Cetrorelix (GnRH) (L) Vasopressin (L,S) Felypressin (L,S) Ganirelix (GnRH) (L) Insulin (E,SS, R) Buserelin (L,S) Eptifibatide Glucagon (E,S,R) Deslorelin (L,S) Bivalirudin (L) Calcitonins (L,S,R) Goserelin (L) Copaxone (L) TRH (L) Histrelin (L) Techtide P-289(S) Gonadorelin (L,S) Leuprolide (L,S) Cubicin (F) Somatostatin (L,S) Nafarelin (S) Fuzeon (antiHIV (H) GHRH (1-29) & (1-44) (S) Tryptorelin (L,S) Ziconotide (pain) (S) CRF (Human & Ovine) (S) Lecirelin (S) Pramlintide (diabetes) (S) Cyclosporin (F) Lanreotide (S) Exenatide (diabetes) (S) Thymopentin (L) Octreotide (L,S) Icatibant (brady-rec) Thymosin Alpha-1 (S) Atosiban (L) Romiplostim (hormon) Secretins (Human & Porcine) (E,S) Desmopressin (L,S) Degarelix (GnRH) Parathyroid Hormone (1-34) & (1-84)(S) Lypressin (L) Mifamurtide (rák, adj.) Vasoactive Intestinal Polypeptide (S) Ornipressin Ecallantide (ödéma) Brain Natriuretic Peptide (R) Pitressin (L) Liraglutide (diabetes) Cholecystokinin (L) ACE Inhibitors (Enalapril, Lisinopril) (L) Tesamorelin Tetragastrin (L) HIV Protease Inhibitors (L) Surfaxin Pentagastrin (L) Peginesatide Eledoisin (L) Carfilzomib Linaclotide (enz.inh) L = in solution; S = on solid phase; E = extraction; F = fermentation; H = hybrid synthesis; R = recombinant; SS = semi-synthesis.
    [Show full text]
  • Exposure to Female Hormone Drugs During Pregnancy
    British Journal of Cancer (1999) 80(7), 1092–1097 © 1999 Cancer Research Campaign Article no. bjoc.1998.0469 Exposure to female hormone drugs during pregnancy: effect on malformations and cancer E Hemminki, M Gissler and H Toukomaa National Research and Development Centre for Welfare and Health, Health Services Research Unit, PO Box 220, 00531 Helsinki, Finland Summary This study aimed to investigate whether the use of female sex hormone drugs during pregnancy is a risk factor for subsequent breast and other oestrogen-dependent cancers among mothers and their children and for genital malformations in the children. A retrospective cohort of 2052 hormone-drug exposed mothers, 2038 control mothers and their 4130 infants was collected from maternity centres in Helsinki from 1954 to 1963. Cancer cases were searched for in national registers through record linkage. Exposures were examined by the type of the drug (oestrogen, progestin only) and by timing (early in pregnancy, only late in pregnancy). There were no statistically significant differences between the groups with regard to mothers’ cancer, either in total or in specified hormone-dependent cancers. The total number of malformations recorded, as well as malformations of the genitals in male infants, were higher among exposed children. The number of cancers among the offspring was small and none of the differences between groups were statistically significant. The study supports the hypothesis that oestrogen or progestin drug therapy during pregnancy causes malformations among children who were exposed in utero but does not support the hypothesis that it causes cancer later in life in the mother; the power to study cancers in offspring, however, was very low.
    [Show full text]
  • Gastric Secretory and Plasma Hormonal Responses to Sham-Feeding of Varying Duration in Patients with Duodenal Ulcer
    Gut: first published as 10.1136/gut.22.12.1003 on 1 December 1981. Downloaded from Gut, 1981, 22,1003-1010 Gastric secretory and plasma hormonal responses to sham-feeding of varying duration in patients with duodenal ulcer S J KONTUREK,* J SWIERCZEK, N KWIECIEN, W OBTUTOWICZ, M DOBRZANSKA, B KOPP, AND J OLEKSY From the Institute ofPhysiology, Medica, Academy, Krakow, and District Hospital, Krakow, Poland SUMMARY Gastric acid and serum gastrin, pancreatic polypeptide, and insulin responses to cephalic vagal stimulation were studied in eight patients with duodenal ulcer using modified sham- feeding for periods varying from four to 30 minutes. In addition, the maximal acid response to sham-feeding was compared with that induced by pentagastrin in 10 healthy subjects and 14 patients with duodenal ulcer. It was found that the gastric acid response to modified sham-feeding reached the maximal value after 15 minutes of sham-feeding and amounted to about 68% of the pentagastrin maximum. The serum pancreatic polypeptide response was also increased after modified sham-feeding and depended on the duration of this procedure, whereas gastrin and insulin responses were not significantly affected by modified sham-feeding. When the peak acid output induced by modified sham-feeding was normalised as percentage of the peak response to pentagastrin, it was similar in healthy subjects and in patients with duodenal ulcer; this indicates that the increased peak acid response to modified sham-feeding observed in patients with duodenal ulcer corresponded with
    [Show full text]
  • Menopausal Hormone Therapy
    GYNAECOLOGY ENDOCRINOLOGY Menopausal hormone therapy: where are we now? Menopausal hormone therapy (MHT) is an effective treatment for symptoms associated with menopause, such as hot flushes, night sweats, mood changes, sleep disturbances and changes in sexual function. While the evidence around MHT has changed over the years, there is now international consensus that the benefits of MHT are likely to outweigh the risks for most women aged < 60 years or within ten years of menopause, for whom menopausal symptoms are affecting their quality of life. KEY PRACTICE POINTS: Every woman’s experience of menopause is different, and Among the oestrogen and progestogen formulations perceptions of menopause vary across cultures. Most available, transdermal oestrogen (funded) and micronised women will experience some menopause symptoms, progesterone (not funded) are associated with the lowest however, only some will seek treatment. risk of adverse effects Menopausal hormone therapy (MHT) is likely to offer overall There is no specific recommended duration for MHT. The benefit to women with menopausal symptoms affecting decision to continue treatment should be reviewed on their quality of life if they are aged < 60 years or within ten an annual basis, taking into account any changes in the years of menopause patient’s risk factors, adverse effects and extent of benefit. Adverse outcomes associated with MHT include breast If women primarily seek assistance for urogenital symptoms cancer, stroke and venous thromboembolism (VTE). of menopause, vaginal products are recommended instead However, the risk of these outcomes depends on factors of MHT. This includes moisturisers, lubricants or a vaginal such as the age or time since menopause when MHT oestrogen cream or pessary.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Study Protocol
    Cover Page for Protocol Sponsor name: Novo Nordisk A/S NCT number NCT02501161 Sponsor trial ID: NN9068-4228 Official title of study: A 104 week clinical trial comparing long term glycaemic control of insulin degludec/liraglutide (IDegLira) versus insulin glargine therapy in subjects with type 2 diabetes mellitus (DUAL™ VIII) Document date: 01 March 2019 IDegLira Date: 01 March 2019 Novo Nordisk Trial ID: NN9068-4228 Version: 1.0 CONFIDENTIAL Clinical Trial Report Status: Final Appendix 16.1.1 16.1.1 Protocol and protocol amendments List of contents Protocol ............................................................................................................................................... Link Appendix A ......................................................................................................................................... Link Appendix B................................................................................................ .......................................... Link Attachment I and II............................................................................................................................ Link Protocol amendment 1 - MX ................................................................ ............................................. Link Protocol amendment 2 - NO.............................................................................................................. Link Protocol amendment 3 - Global/HQ ................................................................................................
    [Show full text]
  • Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
    Reviews/Commentaries/ADA Statements REVIEW ARTICLE Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits 1 4 DANIEL J. DRUCKER, MD RICHARD M. BERGENSTAL, MD ure, weight gain, and, in some analyses, 2 3 STEVEN I. SHERMAN, MD ROBERT S. SHERWIN, MD increased mortality with modest benefit 3 5 FRED S. GORELICK, MD JOHN B. BUSE, MD, PHD on rates of myocardial infarction. This has led to a re-examination of treatment recommendations to minimize the risk ype 2 diabetes is a complex meta- currently available agents exhibit the ideal of cardiovascular morbidity and mortal- bolic disorder characterized by profile of exceptional glucose-lowering ity (3,4) and specifically an interest in T hyperglycemia arising from a com- efficacy to safely achieve target levels of incretin-based therapies in this regard. bination of insufficient insulin secretion glycemia in a broad range of patients. together with resistance to insulin action. Hence, highly efficacious agents that ex- Incretin-based therapies: The incidence and prevalence of type 2 hibit unimpeachable safety, excellent tol- mechanisms of action and benefits diabetes are rising steadily, fuelled in part erability, and ease of administration to The two most recently approved classes of by a concomitant increase in the world- ensure long-term adherence and that also therapeutic agents for the treatment of wide rates of obesity. As longitudinal clearly reduce common comorbidities type 2 diabetes, glucagon-like peptide-1 studies of type 2 diabetes provide evi- and complications of diabetes are clearly (GLP-1) receptor (GLP-1R) agonists and dence linking improved glycemic control needed (Fig.
    [Show full text]
  • Combined Estrogen–Progestogen Menopausal Therapy
    COMBINED ESTROGEN–PROGESTOGEN MENOPAUSAL THERAPY Combined estrogen–progestogen menopausal therapy was considered by previous IARC Working Groups in 1998 and 2005 (IARC, 1999, 2007). Since that time, new data have become available, these have been incorporated into the Monograph, and taken into consideration in the present evaluation. 1. Exposure Data 1.1.2 Progestogens (a) Chlormadinone acetate Combined estrogen–progestogen meno- Chem. Abstr. Serv. Reg. No.: 302-22-7 pausal therapy involves the co-administration Chem. Abstr. Name: 17-(Acetyloxy)-6-chlo- of an estrogen and a progestogen to peri- or ropregna-4,6-diene-3,20-dione menopausal women. The use of estrogens with IUPAC Systematic Name: 6-Chloro-17-hy- progestogens has been recommended to prevent droxypregna-4,6-diene-3,20-dione, acetate the estrogen-associated risk of endometrial Synonyms: 17α-Acetoxy-6-chloro-4,6- cancer. Evidence from the Women’s Health pregnadiene-3,20-dione; 6-chloro-Δ6-17- Initiative (WHI) of adverse effects from the use acetoxyprogesterone; 6-chloro-Δ6-[17α] of a continuous combined estrogen–progestogen acetoxyprogesterone has affected prescribing. Patterns of exposure Structural and molecular formulae, and relative are also changing rapidly as the use of hormonal molecular mass therapy declines, the indications are restricted, O CH and the duration of the therapy is reduced (IARC, 3 C 2007). CH3 CH3 O C 1.1 Identification of the agents CH3 H O 1.1.1 Estrogens HH For Estrogens, see the Monograph on O Estrogen-only Menopausal Therapy in this Cl volume. C23H29ClO4 Relative molecular mass: 404.9 249 IARC MONOGRAPHS – 100A (b) Cyproterone acetate Structural and molecular formulae, and relative Chem.
    [Show full text]